Encapsulation of the HDACi Ex527 into Liposomes and Polymer-Based Particles
Incorporation of drugs into particles can improve their therapeutic effectiveness. Solubility, half-life time, targeting, and the release of the drug can be modified by the encapsulation into a particle. Histone deacetylase inhibitors have a great potential to be used as therapeutics for many different diseases. In this chapter, we describe the inclusion of the low molar mass HDACi Ex527 into polymer-based particles and liposomes.
Key wordsHistone deacetylase inhibitor Ex527 PLGA Acetalated dextran Liposomes Cellular uptake
The authors acknowledge financial support by the Thuringian Ministry of Education, Science and Culture (#B514-09051) within the ProExcellence initiative “NanoConSens.”
- 11.Napper AD, Hixon J, McDonagh T, Keavey K, Pons JF, Barker J, Yau WT, Amouzegh P, Flegg A, Hamelin E, Thomas RJ, Kates M, Jones S, Navia MA, Saunders JO, DiStefano PS, Curtis R (2005) Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem 48(25):8045–8054. doi: 10.1021/jm050522v CrossRefPubMedGoogle Scholar
- 12.Smith MR, Syed A, Lukacsovich T, Purcell J, Barbaro BA, Worthge SA, Wei SR, Pollio G, Magnoni L, Scali C, Massai L, Franceschini D, Camarri M, Gianfriddo M, Diodato E, Thomas R, Gokce O, Tabrizi SJ, Caricasole A, Landwehrmeyer B, Menalled L, Murphy C, Ramboz S, Luthi-Carter R, Westerberg G, Marsh JL (2014) A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington’s disease. Hum Mol Genet 23(11):2995–3007. doi: 10.1093/hmg/ddu010 CrossRefPubMedPubMedCentralGoogle Scholar